The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio. ⋯ Long-term, low-intensity warfarin therapy is a highly effective method of preventing recurrent venous thromboembolism.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. ⋯ The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.